Abstract
Over 200,000 whole genome sequences of SARS-CoV-2 have been determined for viruses isolated from around the world. These sequences have been critical for understanding the spread and evolution of SARS-CoV-2. Using global phylogenomics, we show that mutations frequently occur in the C-terminal end of ORF7a. We have isolated one of these mutant viruses from a patient sample and used viral chal-lenge experiments to demonstrate that Δ115 mutation results in a growth defect. ORF7a has been implicated in immune modulation, and we show that the C-terminal truncation results in distinct changes in interferon stimulated gene expression. Collectively, this work indicates that ORF7a mutations occur frequently and that these changes affect viral mechanisms responsible for suppressing the immune response.
Highlights
ORF7a mutations are found in SARS-CoV-2 genomes isolated from around the globe.
ORF7a mutation results in a replication defect.
An ORF7a mutation limits viral suppression of the interferon response.
Competing Interest Statement
B.W. is the founder of SurGene LLC, and VIRIS Detection Systems Inc. B.W., A. Nemudryi, and A. Nemudraia are inventors on patents related to CRISPR-Cas systems and applications thereof.
Funding Statement
Research in the Wiedenheft lab is supported by the National Institutes of Health (1R35GM134867), the Montana State University Agricultural Experimental Station, the MJ Murdock Charitable Trust, the Gianforte Foundation and the MSU Office of the Vice President for Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Clinical samples were obtained with Montana State University Institutional Review Board approval (protocol #DB033020) and informed consent from patients undergoing testing for SARS-CoV-2 at Bozeman Health Deaconess Hospital
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵3 Twitter: @artemnemudryi
↵4 Twitter: @WiedenheftLab
↵5 Lead contact
We revised Table S1: 1) removed information about the location where samples were acquired 2) changed exact age of patients to age range (5 year intervals) 3) removed the specific dates when samples were acquired. The table now has only the month of sampling
Data Availability
SARS-CoV-2 genome consensus sequences generated in the study were uploaded to GISAID (https://www.gisaid.org/), accession IDs are provided in Supplemental Table S1
